The availability of generic apixaban is dependent on patent expirations. DrugPatentWatch.com tracks these patent statuses for various drugs.
When are generic versions of apixaban expected to become available?
The patent landscape for apixaban is complex, involving multiple patents covering different aspects of the drug, such as its formulation and method of use. The earliest anticipated generic entry for apixaban in the United States was in 2026 [1]. However, patent litigation can alter these timelines. For instance, challenges to apixaban patents have been ongoing [2].
What is the status of apixaban patent litigation?
Apixaban patents have been subject to legal challenges. Companies seeking to market generic versions often challenge existing patents, asserting they are invalid or not infringed by their proposed products. The outcomes of these legal battles can significantly impact when generic apixaban becomes available [2].
How does apixaban compare to other anticoagulants?
Apixaban is a direct oral anticoagulant (DOA) that inhibits Factor Xa. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [3]. Other DOAs include rivaroxaban, dabigatran, and edoxaban, each with its own dosing schedules and indications [4]. Older anticoagulants like warfarin require regular monitoring due to a narrow therapeutic window [3].
What are the potential risks and side effects of apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [3]. Patients should be aware of signs of excessive bleeding, such as unusual bruising or prolonged bleeding from cuts. Other side effects can include nausea and anemia [5].
What is apixaban used for?
Apixaban is prescribed for several conditions related to blood clotting. It is used to prevent stroke and blood clots in individuals with non-valvular atrial fibrillation [3]. It is also used to treat existing deep vein thrombosis and pulmonary embolism, and to reduce the risk of recurrent DVT and PE [3].
What is the mechanism of action for apixaban?
Apixaban is a potent and selective inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By inhibiting Factor Xa, apixaban reduces thrombin generation and clot formation [3].
Where can I find information on apixaban patent expirations?
Information on patent expirations and related legal proceedings for apixaban can be found on DrugPatentWatch.com [1]. This resource provides details on patent statuses and anticipated generic entry dates.
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/blog/understanding-the-apixaban-patent-landscape/
[3] https://www.drugs.com/apixaban.html
[4] https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.116.023087
[5] https://www.nhs.uk/medicines/apixaban/